|
Horizontal Transfer and Antibiotic Resistance
| The use of antibiotic
resistance markers in the development of transgenic
crops has raised concerns about whether transgenic
foods will play a part in our loss of ability to
treat illnesses with antibiotic drugs. The public
is sensitized to this danger because of reports
that some of the antibiotics that we rely on have
lost efficacy after years of misuse through over-prescribing
by doctors and improper use by patients. Animal
husbandry enterprises such as cattle feedlots and
chicken farms routinely use, and often overuse,
antibiotics as part of their feeding or treatment
regimens, leading to publicity about the consequences
of widespread overuse of these defenses against
disease. |

Antibiotic
pills.
Photo: www.molbio.princeton.edu
|
An example of research into this problem is available
at http://bric.postech.ac.kr/science/97now/01_12now/011219c.html.
An advisory committee to Health Canada has submitted
proposals (http://www.hc-sc.gc.ca/vetdrugs-medsvet/amr/e_policy_dev.html#AMR
Report ) for reducing the risk of overuse. "The
Challenge of Antibiotic Resistance", an article
by Levy
(1998) in Scientific American, discusses many facets
of antibiotic resistance.
At several stages
of the laboratory process, developers of transgenic
crops use DNA that codes for resistance to certain antibiotics,
and this DNA often becomes a permanent feature of the
final product although it serves no purpose beyond the
laboratory stage. Will transgenic foods contribute to
the existing problems with antibiotic resistance?
One of the
concerns is related to the risk of horizontal gene transfer,
that is, transfer of DNA from one organism to another
outside of the parent-to-offspring channel. Transfer
of a resistance gene from transgenic food to micro-organisms
that normally inhabit our mouth, stomach, and intestines,
or to bacteria that we ingest along with food, could
help those micro-organisms to survive an oral dose of
antibiotic medicine.
Horizontal transfer of DNA does occur under some natural
circumstances. Small pieces of DNA called plasmids move
from E. coli to several other organisms, and
Agrobacterium tumefaciens facilitates the horizontal
transfer of DNA to produce the disease known as crown
gall in plants. Horizontal transfer of DNA occurs at
very low frequency under laboratory conditions, for
example Acinetobacter, a soil- and water-borne
bacterium (Gebhard
and Smalla, 1998), Streptococcus gordonii,
a cause of dental cavities and heart valve infection
(Mercer
et al., 1999), Aspergillus niger, a fungus
harnessed to produce citric acid for soft drinks (Hoffmann
et al., 1994).
Whether such a transfer could happen frequently in
the special environment of the human gastrointestinal
tract is not known.
Several circumstances would work against a successful
transfer. The acid environment of the stomach degrades
DNA. Mercer
et al. (1999) found that DNA was degraded within
30 seconds when it was mixed with human saliva and hydrochloric
acid in a simulation of the conditions in the human
stomach. And while some organisms take in foreign DNA
under some circumstances, many organisms have mechanisms
to destroy foreign DNA that enters unbidden.
Researchers at the University of Newcastle have reported
that microorganisms in the human digestive system took
up a herbicide resistance gene after the human subjects
ate a meal of GM soy. The experiment was small, involving
12 people with intact digestive systems and 7 who had
undergone colostomies, in which their lower intestines
were removed. In people with intact digestive systems,
no GM DNA was found in the stools and no microorganisms
took up GM DNA. But in people who had undergone colostomies,
about 4 percent of the GM DNA survived the trip through
the abbreviated intestinal tract and a small number
of microorganisms took up GM DNA. The GM DNA in this
experiment was a herbicide resistance gene rather than
an antibiotic resistance gene, but the results suggest
that horizontal transfer of GM DNA can occur in the
human digestive tract under some circumstances. News
reports on this experiment are available at http://www.newscientist.com/news/news.jsp?id=ns99992565
and http://www.guardian.co.uk/gmdebate/Story/0,2763,756666,00.html.
A report from the researchers at the University of Newcastle
is available at http://www.food.gov.uk/multimedia/pdfs/gmnewcastlereport.PDF.
The information pertaining to this experiment begins
on page 22 of the report.
Some scientists think that a successful transfer of
DNA from transgenic plants would not occur frequently
enough to be detectable or to cause health problems
in humans. However the actual rate of transfer under
natural conditions is unknown because of a lack of research
into this particular circumstance. The EU has engaged
scientists to assess the risk of horizontal gene transfer
from genetically modified foods (http://europa.eu.int/comm/research/quality-of-life/gmo/04-food/04-07-project.html).
A second concern about the use of antibiotic resistance
genes is that some (though not all) resistance genes
work by producing an enzyme that destroys or inactivates
the targeted antibiotic. If such a resistance gene continues
to function after it has outlived its usefulness in
the laboratory, it might produce low levels of the resistance
enzyme in the plant parts that we eat. While high processing
temperatures would inactivate the enzyme in processed
foods, ingestion of fresh or raw transgenic foods could
result in the stomach containing a small amount of an
enzyme that inactivates an orally administered dose
of the antibiotic. Will a person taking prescribed antibiotics
endanger the success of the treatment if he eats a meal
of transgenic food?
The FDA faced
this issue in 1993 when it considered whether to approve
Calgene's FlavrSavr tomato, which contained a gene for
resistance to kanamycin, neomycin, gentamicin A and
gentamicin B, all of which are sometimes used to fight
infections in humans. In FDA tests using a simulation
of a human stomach, the enzyme was degraded by stomach
acids before it could attack orally administered antibiotics.
A report on the FDA's evaluation is available at http://vm.cfsan.fda.gov/~dms/opa-armg.html.
Scroll down to "Appendix 1. Evaluation of the safety
of the kanamycin resistance gene as a selectable marker"
for a discussion of the FDA's findings.
Ciba-Geigy's
Bt corn 176 also contained a gene for resistance to
an antibiotic used in the treatment of human diseases.
Ampicillin, a member of the penicillin family, is one
of the most widely prescribed antibiotics, often used
to fight infections of the ear, bladder, and kidney.
In Bt corn 176 the ampicillin resistance gene was constructed
so that it was active only in prokaryotic organisms,
such as bacteria. This feature made it useful for early
stages of development of the crop. The gene was not
active in eukaryotic organisms, or "higher" plants,
such as corn. Tests showed that no ampicillin-inactivating
protein was produced in corn plants that contained the
gene, so the presence of the resistance gene was not
viewed as a problem when Bt corn 176 went through the
approval process in 1995 in Canada and the United States.
Details of the transgenes in Bt 176 and the factors
considered in approving the use of the ampicillin resistance
gene are available from the USDA (http://www.aphis.usda.gov/biotech/dec_docs/9431901p_det.HTM)
for the U.S. process and from the Canadian Food Inspection
Agency (http://inspection.gc.ca/english/plaveg/pbo/dd/dd9609e.shtml)
for the Canadian process. (Bt 176 was discontinued in
2001 for reasons unrelated to the ampicillin resistance
gene. See our Discontinued
Products page for more information.)
For additional
information on the potential risk from antibiotic resistance
genes, see the Royal Society's 2002 report "Genetically
modified plants for food use and human health--an update"
(http://www.royalsoc.ac.uk/files/statfiles/document-165.pdf).
While the risks
from antibiotic resistance genes in transgenic plants
appear to be low, steps are being taken to reduce the
risk and to phase out their use.
- The FDA recommends that developers of transgenic
crops use antibiotics that are not commonly used for
treatment of diseases in humans. Thus, if horizontal
gene transfer does occur, micro-organisms in the body
are not likely to have acquired resistance to the
antibiotics that a doctor might prescribe to fight
infection.
- Scientists are changing their development methods.
Other marker genes, such as green fluorescent protein,
or mannose (Joersbo
et al., 1998), may be able to do the job that
antibiotic resistance markers have done.
- Scientists are also experimenting with methods
for removing the antibiotic resistance genes before
the plants are released for commercial use (Dale
and Ow, 1991; Ebinuma
et al., 1997; Iamtham
and Day, 2000; Zuo
et al., 2001), so that these genes can be used
during development and then eliminated from the final
product.
- European scientists have developed a method for
inactivating the antibiotic resistance genes in the
event that they are transferred to bacteria in the
digestive system of animals or humans (Libiakova
et al., 2001). A special DNA sequence inserted
into the antibiotic resistance gene will prevent the
gene from functioning inside a bacterium. Plants are
able to snip out the special sequence to let the gene
function correctly.
The possibility of enhanced antibiotic resistance in
the soil is also an issue of interest in connection
with the use of these markers. See our
discussion for more information.
|